Search
VidPrevtyn Beta
go.drugbank.com/drugs/DB16427Approved[L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from … [A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691]
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022. … [A228493] However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma are lacking.
Tegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalIt is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327]. … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the
International brands: ESUEEW AN TArtesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria. … [A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923] … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas
Potassium gluconate
go.drugbank.com/drugs/DB13620ApprovedPotassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function [A32222]. … In dietary supplements, potassium is often present as potassium chloride, but many other forms—including potassium citrate, phosphate, aspartate, bicarbonate, and **gluconate**—are also used [L2652].
Mixtures: Cal-mag Plus K, Mn and Zn Caplets, Multivitamins and Minerals for Young MenZinc sulfate
go.drugbank.com/drugs/DB09322ApprovedInvestigationalIt is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Mixtures: Nutrol E-400 Plus Zinc Et Selenium Cap, Supravite Stress Avec Vit E Cuivre Et ZincProducts: Micro ZnLazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalenzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. … [A7354] Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting
Categories: Agents Acting on the Renin-Angiotensin SystemGemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigational[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. … [L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]
International brands: Gen-Fibro